NeuPath Health Inc
XTSX:NPTH
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/FCFF
Enterprise Value to Free Cash Flow to Firm (EV/FCFF) ratio compares a company`s total enterprise value to the free cash flow available to all investors, both debt and equity holders. It shows how much investors are paying for each dollar of cash flow the business generates before interest payments.
Enterprise Value to Free Cash Flow to Firm (EV/FCFF) ratio compares a company`s total enterprise value to the free cash flow available to all investors, both debt and equity holders. It shows how much investors are paying for each dollar of cash flow the business generates before interest payments.
Valuation Scenarios
If EV/FCFF returns to its 3-Year Average (7.3), the stock would be worth CA$0.34 (42% downside from current price).
| Scenario | EV/FCFF Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 12.6 | CA$0.58 |
0%
|
| 3-Year Average | 7.3 | CA$0.34 |
-42%
|
| 5-Year Average | 6.8 | CA$0.31 |
-46%
|
| Industry Average | 20.5 | CA$0.94 |
+62%
|
| Country Average | 20.4 | CA$0.94 |
+62%
|
Forward EV/FCFF
Today’s price vs future free cash flow to firm
Peer Comparison
| Market Cap | EV/FCFF | P/E | ||||
|---|---|---|---|---|---|---|
| CA |
|
NeuPath Health Inc
XTSX:NPTH
|
32.7m CAD | 12.6 | -45.5 | |
| US |
|
CVS Health Corp
NYSE:CVS
|
102.9B USD | 19.6 | 58.2 | |
| US |
C
|
Cigna Group
XMUN:CGN
|
70.3B EUR | 12.3 | 13.6 | |
| US |
|
Cigna Corp
NYSE:CI
|
75.1B USD | 0 | 12.6 | |
| DE |
|
Fresenius Medical Care AG
XMUN:FME
|
22.6B EUR | 16.7 | 23.1 | |
| DE |
|
Fresenius SE & Co KGaA
XETRA:FRE
|
23B EUR | 29.6 | 18.2 | |
| US |
|
Quest Diagnostics Inc
NYSE:DGX
|
21.7B USD | 19.9 | 21.2 | |
| US |
|
Laboratory Corporation of America Holdings
NYSE:LH
|
21.3B USD | 21.4 | 24.3 | |
| DE |
F
|
Fresenius Medical Care AG & Co KGaA
XETRA:FME
|
10.8B EUR | 10 | 11.1 | |
| US |
|
Guardant Health Inc
NASDAQ:GH
|
10.9B USD | -48.7 | -26.1 | |
| US |
|
DaVita Inc
NYSE:DVA
|
10.3B USD | 14.9 | 13.8 |
Market Distribution
| Min | 0 |
| 30th Percentile | 13.1 |
| Median | 20.4 |
| 70th Percentile | 33.5 |
| Max | 22 577.3 |
Other Multiples
NeuPath Health Inc
Glance View
NeuPath Health, Inc. operates as a healthcare services company that provides chronic pain management services. The company is headquartered in Mississauga, Ontario and currently employs 165 full-time employees. The company went IPO on 2019-12-03. The firm operates a network of medical clinics in Ontario and Alberta, in addition to an independent medical assessment business with a national network of health care providers. Its medical clinics provide assessments and rehabilitation services to clients with chronic pain, musculoskeletal/back injuries, sports related injuries and concussions. The firm's health care providers cover a range of specialties and include physiatrists, neurologists, anesthesiologists, general practitioners with specialized training in chronic pain, as well as medication management physicians, athletic therapists and nurses. In addition, the Company provides independent medical assessments through health care providers, including cardiologists, dentists, dermatologists, endocrinologists, psychiatrists and gastroenterologists, among others.
